These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11096152)

  • 1. Circulating levels of matrix metalloproteinases MMP-3 and MMP-2 in renal transplant recipients with chronic transplant nephropathy.
    Rodrigo E; López-Hoyos M; Escallada R; Fernández-Fresnedo G; Ruiz JC; Piñera C; Cotorruelo JG; Zubimendi JA; de Francisco AL; Arias M
    Nephrol Dial Transplant; 2000 Dec; 15(12):2041-5. PubMed ID: 11096152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in matrix metalloproteinases and their inhibitors in kidney transplant recipients.
    Ahmed AK; El Nahas AM; Johnson TS
    Exp Clin Transplant; 2012 Aug; 10(4):332-43. PubMed ID: 22845765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
    Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.
    Chang HR; Yang SF; Li ML; Lin CC; Hsieh YS; Lian JD
    Clin Chim Acta; 2006 Apr; 366(1-2):243-8. PubMed ID: 16313894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection.
    Laplante A; Liu D; Demeule M; Annabi B; Murphy GF; Daloze P; Chen H; Béliveau R
    Transpl Int; 2003 Apr; 16(4):262-9. PubMed ID: 12730807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal dysfunction and intragraft proMMP9 activity in renal transplant recipients with interstitial fibrosis and tubular atrophy.
    Racca MA; Novoa PA; Rodríguez I; Della Vedova AB; Pellizas CG; Demarchi M; Donadio AC
    Transpl Int; 2015 Jan; 28(1):71-8. PubMed ID: 25179305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury.
    Mazanowska O; Kamińska D; Krajewska M; Zabińska M; Kopeć W; Boratyńska M; Chudoba P; Patrzalek D; Klinger M
    Transplant Proc; 2011 Oct; 43(8):3000-3. PubMed ID: 21996210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of serum and urinary matrix metalloproteases/tissue inhibitors of metalloproteases with subclinical allograft fibrosis in renal transplantation.
    Hirt-Minkowski P; Marti HP; Hönger G; Grandgirard D; Leib SL; Amico P; Schaub S
    Transpl Immunol; 2014 Jan; 30(1):1-6. PubMed ID: 24291496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 Gene Polymorphisms on Allograft Rejection in Pediatric Renal Transplant Recipients.
    Akad Dincer S; Sahin FI; Terzi YK; Gulleroglu K; Baskin E; Haberal M
    Exp Clin Transplant; 2023 Apr; 21(4):333-337. PubMed ID: 32799785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of serum matrix metalloproteinases MMP-2 and MMP-9 after human liver transplantation: increased serum MMP-9 level in acute rejection.
    Kuyvenhoven JP; Verspaget HW; Gao Q; Ringers J; Smit VT; Lamers CB; van Hoek B
    Transplantation; 2004 Jun; 77(11):1646-52. PubMed ID: 15201662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
    Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute rejection-associated tubular basement membrane defects and chronic allograft nephropathy.
    Bonsib SM; Abul-Ezz SR; Ahmad I; Young SM; Ellis EN; Schneider DL; Walker PD
    Kidney Int; 2000 Nov; 58(5):2206-14. PubMed ID: 11044243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
    Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
    Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients.
    Chang HR; Kuo WH; Hsieh YS; Yang SF; Lin CC; Lee ML; Lian JD; Chu SC
    Transl Res; 2008 Apr; 151(4):217-23. PubMed ID: 18355769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A disproportionately greater body weight of the recipient in regards to the donor causes chronic graft nephropathy. A study of paired kidneys.
    Andrés A; Mazuecos A; García García-Doncel A
    Nephrol Dial Transplant; 2004 Jun; 19 Suppl 3():iii21-5. PubMed ID: 15192131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine excretion of transforming growth factor-beta1 in chronic allograft nephropathy.
    Boratyńska M
    Ann Transplant; 1999; 4(2):23-8. PubMed ID: 10850587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia.
    Karapanagiotidis GT; Antonitsis P; Charokopos N; Foroulis CN; Anastasiadis K; Rouska E; Argiriadou H; Rammos K; Papakonstantinou C
    J Cardiothorac Surg; 2009 Nov; 4():59. PubMed ID: 19886986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.